Berlin, February 18, 2019. The merger between Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) as absorbing company with the Belgian Eckert & Ziegler BEBIG SA (EZB) as absorbed company has become formally effective with today’s entry into the commercial register of Berlin-Charlottenburg. As a result, trading in BEBIG shares listed on Euronext Brussels (ISIN BE0974300320) will cease on February 18, 2019.
BEBIG shares will be converted into EZAG shares (ISIN DE0005659700) at a ratio of 5.3:1. Securities processing is being performed by Quirin Privatbank, Berlin and is expected to be completed by the end of March.
Eckert & Ziegler Strahlen- und Medizintechnik AG will use a total of 84,358 of its own EZAG shares when converting the 447,096 BEBIG shares.
The objective of the merger is to streamline the corporate structure of the EZAG Group as well as the associated regulatory reporting. Dual stock exchange listings within the group mean higher administrative expenditures that are compensated by only minor economic benefits. Ending the stock exchange listing and the thus associated cost savings, reduces the annual expenditure of EZB significantly, including the statutory audit of the annual accounts.
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.
Contributing to saving lives.
Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com